What We're Reading: Page 300
Industry reads hand-picked by our editors
May 15, 2017
-
Crain's Detroit Business
Life after Pfizer: A decade later, Michigan pharmaceutical companies have found paths to growth
-
The Boston Globe
Henri Termeer, key biotech leader who built Genzyme into an industry giant, dead at 71
-
Forbes
Pharma's not so stingy with R&D after all
-
Phys.org
Cutting-edge analysis reveals how different drugs interact with the same target
May 12, 2017
May 11, 2017
-
San Francisco Business Times
Gilead's last chronic HIV drug — and what it plans to do now
-
Xconomy
Stalled, or rising momentum? New York wrestles with its biotech future
-
Pharmaceutical Processing
Global pharma market roundtable: China vs. Ireland
-
The San Diego Union-Tribune
Mice with trouble eating, mating, reveal potential arthritis drug
May 10, 2017
May 09, 2017
-
Bloomberg
Ackman, Valeant still joined at hip as insider trade suit looms
-
Ars Technica
Big Pharma hopes research spending — not reasonable pricing — will improve image
-
Reuters
EpiPens should work at least a while past expiration dates
-
The Washington Post
Guinea pigs or pioneers? How Puerto Rican women were used to test the birth control pill
May 08, 2017
-
St. Louis Post-Dispatch
Express Scripts battle with Anthem raises questions about drug prices
-
Financial Times
Fears over farm links to pharma
-
The Guardian
‘I don’t know who I am without it’: the truth about long-term antidepressant use
May 05, 2017
-
Boston Business Journal
Pharma’s holy grail: Bay State biotechs seek a drug for Alzheimer’s
-
The Economist
Breaking down the walls: The remarkable promise of cell-free biology
-
Kaiser Health News
Louisiana proposes tapping a federal law to slash hepatitis C drug prices
-
The Boston Globe
Former Harvard researcher says school excluded him from drug company royalites
Previous
